Promising directions in the development of new vaccines against papillomavirus infection

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Papillomavirus infection is one of the most common viral infections worldwide. Highly oncogenic types of human papillomavirus (HPV) are the root cause of cancer of the cervix, vulva, vagina, genitals in men, anal cancer, as well as cancer of the oropharyngeal region. Currently, three HPV vaccines have been registered and successfully used in Russia: divalent (HPV types 16, 18) and quadrivalent (HPV types 6, 11, 16, 18). In the countries of America and Europe, a nine-valent vaccine is available, which contains nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, 58). These vaccines are preventive, have high immunogenicity and induce the production of specific antibodies. The action of preventive vaccines is aimed at creating specific humoral immunity to the capsid proteins of the virus, which leads to the prevention of HPV infection. Nevertheless, there are no specific medicines on the pharmaceutical market aimed at treating an already established pathology.

Currently, active development of HPV vaccines with both preventive and therapeutic effects is underway. Candidates of therapeutic HPV vaccines undergo various stages of research. Experimental vaccination systems on animal models provide encouraging results. If preventive and therapeutic HPV vaccines prove to be effective in patients as well as in animal models, then pillomavirus infection and related malignant diseases can be controlled by vaccination.

Texto integral

Acesso é fechado

Sobre autores

Tatiana Nikitina

FSBI NCESMP of the Ministry of Health of Russia

Autor responsável pela correspondência
Email: tatyana-gisk@yandex.ru

кандидат медицинских наук, главный эксперт управления аллергенов, цитокинов и других иммуномодуляторов Центра экспертизы и контроля медицинских иммунобиологических препаратов 

Rússia, Moscow

Natalya Rayevskaya

FSBI NCESMP of the Ministry of Health of Russia

Email: raevskayanm@expmed.ru

к.б.н., эксперт управления аллергенов, цитокинов и других иммуномодуляторов Центра экспертизы и контроля медицинских иммунобиологических препаратов 

Rússia, Moscow

Irina Solovieva

Ulyanovsk State University

Email: irsol126@mail.ru

доктор медицинских наук, профессор кафедры педиатрии

Rússia, Ulyanovsk

Andrey Simbirtsev

State research institute of Highly Pure Biopreparations Federal Medico-Biological Agency

Email: a.s.simbirtsev@hpb.spb.ru

доктор медицинских наук, профессор, чл.-корр. РАН, научный руководитель 

Rússia, St. Petersburg

Andrey Volgin

FSBI NCESMP of the Ministry of Health of Russia

Email: volgin@regmed.ru

кандидат медицинских наук, заместитель директора Центра экспертизы и контроля медицинских иммунобиологических препаратов 

Rússia, Moscow

Bibliografia

  1. Козлов Д.Г., Чеперегин С.Э., Губайдуллин И.И., Ефремов Б.Д., Тюрин О.В., Залунин И.А. Способ получения белка Е7-HSP70 и штамм дрожжей Saccharomyces cerevisiae для его осуществления // Патент РФ 2489481. 2013.
  2. Kozlov D.G., Cheperegin S.E., Gubajdullin I.I., Efremov B.D., Tjurin O.V., Zalunin I.A. Method to produce protein E7-HSP70 and yeast strain Saccharomyces cerevisiae for its realization // Patent RU2489481C1. 2013. Russian.
  3. Холопов Д.В., Вязовая А.А., Лялина Л.В., Алексеева Д.А., Молчанов С.В., Нарвская О.В., Топузов Э.Э. Вирус папилломы человека при злокачественных новообразованиях различных локализаций // Вопросы онкологии. 2023. Т. 69, № 1. С. 89-94.
  4. Kholopov D., Vyazovaya А., Lyalina L., Alekseeva D., Molchanov S., Narvskaya O., Topuzov Е. Human papillomavirus in malignant neoplasms of different localizations // Voprosy Onkologii. 2023. Vol. 69, №1 Р. 89-94.
  5. Abdulwahab A Oyouni A. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines // J of Infection and Public Health. 2023. Vol. 16, № 4. Р. 626-631.
  6. Akhatova A., Chan C., Azizan A., Aimagambetova G. The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervical cancer: systematic review // Vaccines. 2022. Vol. 10, № 1. P. 53.
  7. Boilesen D., Neckermann Р., Willert Т., Müller М., Schrödel S., Pertl C., Thirion C., Asbach B., Wagner R., Holst Р. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1 E2 E6 E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice // J Cancer Immunology Research. 2023. Vol. 11, № 2. Р. 261-275.
  8. Cai H., Feng Y., Fan P., Guo Y., Kuerban G., Chang C., Yao X., Peng Y., Wang R. HPV16 E6-specific T cell response and HLA-A alleles are related to the prognosis of patients with cervical cancer // J Infectious Agents and Cancer. 2021. Vol. 16, № 1. Р. 61.
  9. Chabeda A., Yanez R., Lamprecht R., Meyers A., Rybicki E., Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases // Papillomavirus Res. 2018. Vol. 5. P. 46-58.
  10. Chen J., Wang D., Wang Z., Wu K., Wei S., Chi X., Qian C., Xu Y., Zhou L., Li Y., Zhang S., Li T., Kong Z., Wang Y., Zheng Q., Yu H., Zhao Q., Zhang J., Xia N., Li S., Gu Y. Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16 // Virology 2023. doi: 10.1128/jvi.01819-22.
  11. Chen Х., Garcea R., Goldberg I., Cazini G., Harrison S. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 // Mol Cell. 2000. Vol. 5, № 3. P. 557-567.
  12. Cheng W., Hung C., Chai C., Hsu K., He L., Ling M., Wu T. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. // J Virol. 2001. Vol. 75, № 5. P. 2368-2376.
  13. Chu N., Wu H., Wu T., Boux L., Mizzen L., Siegel M. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7 // Cell Stress Chaperones. 2000. Vol. 5, № 5. P. 401-405.
  14. Chuang C., Monie A., Wu A., Hung C. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects // J Biomed Sci. 2009. Vol. 16, № 1. P. 49.
  15. Clark К., Cornelia L Trimble С. Current status of therapeutic HPV vaccines // Gynecologic oncology. 2020. Vol. 156, № 2. Р. 503-510.
  16. Çuburu N., Kim R., Guittard G., Thompson C., Day P., Hamm D., Pang Y., Graham B., Lowy D., Schiller J. A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells // J Immunol. 2019. Vol. 202, № 4. P. 1250-1264.
  17. Gardella B., Gritti A., Soleymaninejadian E., Francesca Pasquali M., Riemma G., La Verde M., Schettino M., Fortunato N., Torella M., Dominoni M. New Perspectives in Therapeutic Vaccines for HPV // J Medicina (Kaunas). 2022. Vol. 58, № 7. Р. 860.
  18. Khairkhah N., Bolhassani A., Najafipour R. Current and future direction in treatment of HPV-related cervical disease // Journal of Molecular Medicine. 2022 . Vol. 100, № 6. Р. 829-845.
  19. Kumar A., Rai P. Recent advances and strategies in vaccine development against HPV // Immunopathology, Diagnosis and Treatment of HPV Induced Malignancies. 2022. Р. 149-163.
  20. Laganà A., Chiantera V., Gerli S., Proietti S., Lepore E., Unfer V., Carugno J., Favilli A. Preventing рersistence of HPV Infection with natural molecules // Pathogens. 2023. Vol. 12, № 3. Р. 416.
  21. Lin C., Hung C., Juang J., Не L., Lin K., Kim T., Wu T. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles // Molecular Therapy. 2003. Vol. 8, № 4. P. 559–566.
  22. Liu Y., Li H., Pi R., Yang Y., Zhao X., Qi X. Current strategies against persistent human papillomavirus infection // Int J of Oncology. 2019. Vol.55, № 3. Р. 570-584.
  23. Maciag P., Radulovic S., Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix // Vaccine. 2009. Vol. 27, № 30. P. 3975-3983.
  24. Mackova J., Kutinova L., Hainz P., Krystofova J., Sroller V., Otahal P., Gabriel P., Nemeckova S. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12 // Int J Oncol. 2004. Vol. 24, № 6. P. 1581-1588.
  25. Markowitz L., Schiller J. Human Papillomavirus Vaccines // J Infect Dis. 2021. Vol. 224 № 12 (дополнение 2) P. 367-378.
  26. Mikysková R., Indrová M., Símová J., Jandlová T., Bieblová J., Jinoch P., Bubeník J., Vonka V. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF // Int J Oncol. 2004. Vol. 24, № 1. P. 161-167.
  27. Murakami M., Gurski KJ., Marincola FM., Ackland J., Steller MA. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells // Cancer Res. 1999. Vol. 15-59, № 6. P. 1184-1187.
  28. Nardelli-Haefliger D., Lurati F., Wirthner D., Spertini F., Schiller J.T., Lowy D., Ponci F., De Grandi P. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine // Vaccine. 2005 Vol. 23, № 28. P. 3634-3641.
  29. Opp S., Hurtado A., Pampeno C., Lin Z., Meruelo D. Potent and Targeted Sindbis Virus Platform for Immunotherapy of Ovarian // J Cells. 2022. Vol. 12, № 1. Р. 77.
  30. Parkin D. The global health burden of infection-associated cancers in the year 2002 // Int J Cancer. 2006. Vol. 118. № 12. P. 3030-3044.
  31. Peng S., Ferrall L., Gaillard S., Wang C., Chi W.Y., Huang C.H., Roden R.B.S., Wu T.C., Chang Y.N., Hung C.F. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody // mBio. 2021. Vol. 12. № 1. e03224-20.
  32. Peng S., Kim T., Lee J., Yang M., He L., Hung C., Wu T. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life // Hum Gene Ther. 2005. Vol. 16, № 5. P. 584-593.
  33. Peng X., Woodhouse I., Hancock G., Parker R., Marx K., Müller J., Salatino S., Partridge T., Nicastri A., Liao H., Kruppa G., Hellner K., Dorrell L., Ternette N.. Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer // Updates on HPV Vaccination Ojone Illah, Adeola Olaitan Diagnostics. 2023. Vol.13, № 2. Р. 243.
  34. Ponduri А., Azmy М., Axler Е., Lin J, Schwartz R., Chirilă М., Dikkers F., Yang C., Mehta V., Gangar M. The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis // The Laryngoscope. 2023. doi: 10.1002/lary.30560.
  35. Pushko P., Parker M., Ludwig G., Davis N., Johnston R., Smith J. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo // Virology. 1997. Vol. 22-239, № 2. P. 389-401.
  36. Rechtsteiner G., Warger T., Osterloh P., Schild H., Radsak M. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod // J Immunol. 2005. Vol. 1-174, № 5. P. 2476-2480.
  37. Rittich S., Dushkova M., Mackova J., Pokorna D., Jinoch P., Smahel M. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2 // Oncology Reports. 2005. Vol. 13, № 2. P. 311-317.
  38. Roden R., Ling M., Wu T. Vaccination to prevent and treat cervical cancer // Hum Pathol. 2004 Vol. 35, № 8. P. 971-982.
  39. Roden R., Monie A., Wu T.C. Opportunities to improve the prevention and treatment of cervical cancer // Curr Mol Med. 2007 Vol. 7, № 5. P. 490-503.
  40. Rosales R., López-Contreras M., Rosales C., Magallanes-Molina J., Gonzalez-Vergara R., Arroyo-Cazarez J., Ricardez-Arenas A., Del Follo-Valencia A., Padilla-Arriaga S., Guerrero M., Pirez M., Arellano-Fiore C., Villarreal F. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine // Hum Gene Ther. 2014. Vol. 25, № 12. P. 1035-1049.
  41. Rose R., White. W., Li M., Suzich J. Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies // J. Virol. 1998. Vol. 72, № 7. P. 6151-6154.
  42. Samuels S., Marijne Heeren A., Zijlmans HJMAA., Welters M., van den Berg J., Philips D., Kvistborg P., Ehsan I., Scholl SME, Nuijen B., Schumacher T., van Beurden M., Jordanova E., Haanen JBAG., van der Burg S., Kenter G. HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia // Cancer Immunol Immunother. 2017. Vol. 66, № 9. P. 1163-1173.
  43. Santin A., Bellone S., Roman J., Burnett A., Cannon M., Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy // Curr Pharm Des. 2005. Vol. 11, № 27. P. 3485-500.
  44. Schmitt E., Gehrmann M., Brunet M., Multhoff G., Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy // J Leukoc Biol. 2007. Vol. 81, № 1. P. 15-27.
  45. Stanley M. HPV vaccines: alternative dosage schedules // J Expert Review of Vaccines. 2019. Vol. 18, № 12. Р. 1309-1316.
  46. Tang J., Li Mi., Zhao C., Shen D., Liu L., Zhang X., Wei L. Therapeutic DNA vaccines against HPV-related malignancies: promising leads from clinical trials // J Viruses. 2022. Vol. 14, № 2. Р. 239.
  47. Thompson P., Dessureault S. Tumor cell vaccines // Adv Exp Med Biol. 2007. Vol. 601. Р. 345-355.
  48. Tillman B., Hayes T., DeGruijl T., Douglas J., Curiel D. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model // Cancer Res. 2000. Vol. 1-60, № 19. P. 5456-5463.
  49. Trimble C., Morrow M., Kraynyak K., Shen X., Dallas M., Yan J., Edwards L., Parker R., Denny L., Giffear M., Brown A., Marcozzi-Pierce K., Shah D., Slager A., Sylvester A., Khan A., Broderick K., Juba R., Herring T., Boyer J., Lee J., Sardesai N., Weiner D., Bagarazzi. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial // Lancet. 2015. Vol. 386, № 10008. P. 2078-2088.
  50. Trimble C., Peng S., Kos F., Gravitt P., Viscidi R., Sugar E., Pardoll D., Wu T. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3 // Clin Cancer Res. 2009. Vol. 1-15, № 1. P. 361-3676.
  51. Tseng C., Trimble C, Zeng Q., Monie A., Alvarez R., Huh W., Hoory T., Wang M., Hung C., Wu T. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts // Cancer Immunol Immunother. 2009. Vol. 58, № 5. P. 737-748.
  52. Wang T., Ling M., Shih I., Pham T., Pai S., Lu Z., Kurman R., Pardoll D., Wu T. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity // Gene Ther. 2000. Vol. 7, № 9. P. 726-733.
  53. Wlazlo A., Dеng Н., Gilles-David W. DNA vaccines against cancer proteins E6 or E7 of human papillomavirus type 16 // Cancer Gene Therapy. 2004. Vol. 11, № 6. P. 457-464.
  54. Yaomei Tian, Die Hu, Yuhua Li, Li Yang. Development of therapeutic vaccines for the treatment of diseases // J Molecular Biomedicine. 2022. Vol. 3, № 1. Р. 40.
  55. Zhou J., Jou J., Cohen E. Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers // Cancers. 2022. Vol. 14, № 1. Р. 33.
  56. Zhou L., Ma Y., Wang K., Chen T., Huang Y., Liu L., Li Y., Sun J., Hu Y., Li T., Kong Z., Wang Y., Zheng Q., Zhao Q., Zhang J., Gu Y., Yu H., Xia N., Li S. Omics-guided bacterial engineering of Escherichia coli ER2566 for recombinant protein expression // Applied Microbiology and Biotech. 2022. Vol. 107, № 2-3. P. 853-865.
  57. Zhuang S., Monin A., Wu A., Hong S. The combination of apigenin treatment with therapeutic vaccination against HPV DNA leads to an increased therapeutic antitumor effect // Doctor of Medical Sciences. 2009. Vol. 16. P. 49.
  58. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application // Nat Rev Cancer. 2002. Vol. 2, № 5. P. 342-350.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Nikitina T.N., Rayevskaya N.M., Solovieva I.L., Simbirtsev A.S., Volgin A.R., 2023

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies